Precipio Announces Q4 2017 Revenue at 350% of Previous Quarter NEW HAVEN, Conn., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces preliminary, unaudited revenues for the 4th quarter of 2017 of approximately...

Precipio Enters Japanese Liquid Biopsy Market with First Hospital Sale NEW HAVEN, Conn., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces its entry into the Japanese market with a first order of its ICE-COLD PCR™...

Precipio Commences Validation Study of Proprietary IV-Cell Cytogenetics Media at University of Pennsylvania NEW HAVEN, Conn., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics firm Precipio, Inc. (NASDAQ:PRPO), today announced it is collaborating with the cytogenetics laboratory at the University of...

Precipio Appoints New Sales VP to Manage Diagnostics Sales Expansion NEW HAVEN, Conn., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics firm Precipio, Inc. (NASDAQ:PRPO) has appointed Douglas Sites to the new position of Vice President of Sales where he will...

Yale Study Demonstrates Four-Fold Superiority of Academic Level Diagnostic Accuracy NEW HAVEN, Conn., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced preliminary data from an ongoing study on the impact of academic...